Many physicians, and even some Mens Clinics, require patients to come in once a week for an IM injection
Proper injection technique for GLP-1 medications includes using different anatomical sites in a structured rotation pattern

Key findings from published and presented studies include: In a phase 2 obesity trial, higherdose retatrutide produced average weight loss of around 22.824.2% over 48 weeks in people with obesity. In participants with type 2 diabetes, retatrutide achieved substantial weight loss and marked improvements in blood sugar and cardiometabolic markers, though average percentage weight loss was somewhat lower than in nondiabetic obesity cohorts. Early studies also reported significant reductions in liver fat and visceral adipose tissue, with a high proportion of participants with fatty liver disease showing resolution of hepatic steatosis at higher doses. These results have led several reviews to describe retatrutide as a potential game changer in obesity pharmacotherapy, representing the first GLP1/GIP/glucagon triple agonist with robust human data. Popular coverage has highlighted phase 3 data suggesting average weight losses approaching 29% of body weight in some cohorts (roughly 71 pounds), which is about double typical results with semaglutide over comparable periods

For every-other-day shampoo users : Apply nightly before bed, regardless of wash day
Clinical studies on weight loss have proven that people using semaglutide can shed as much as 15% of their body weight when they use it in addition to a healthy diet and exercise